Videos about MMN

Optimizing IgG Therapy in Chronic Autoimmune Neuropathies
Jeffrey A. Allen, MD
University of Minnesota
12:50 MIN
  • CIDP
  • MMN
Review options for individualizing treatment and tools used to assess IgG performance
DOWNLOAD PDF
Pathogenesis and Mechanism of Action of Inflammatory Neuropathies
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
13:53 MIN
  • CIDP
  • GBS
  • MMN

Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.

DOWNLOAD PDF
SCIg in Multifocal Motor Neuropathy
Hans D. Katzberg, MD, MSc, FRCP(C)
University Health Network /Toronto General Hospital Canada
10:32 MIN
  • MMN

Hear the results of a trial to determine the feasibility of switching patients with multifocal motor neuropathy on intravenous to subcutaneous immunoglobulin.

DOWNLOAD PDF
Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
3:00 MIN
  • CIDP
  • MMN

Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

DOWNLOAD PDF
NOW PLAYING
12:50
Optimizing IgG Therapy in Chronic Autoimmune Neuropathies
Review options for individualizing treatment and tools used to assess IgG performance
NOW PLAYING
13:53
Pathogenesis and Mechanism of Action of Inflammatory Neuropathies

Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.

NOW PLAYING
10:32
SCIg in Multifocal Motor Neuropathy

Hear the results of a trial to determine the feasibility of switching patients with multifocal motor neuropathy on intravenous to subcutaneous immunoglobulin.

NOW PLAYING
3:00
Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic...

Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

Our Experts on MMN

Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
Nabil Moumane, MD
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
  • CIDP
  • MMN
Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring.
Jeffrey A. Allen, MD
University of Minnesota
Jeffrey A. Allen, MD
University of Minnesota
  • CIDP
  • MMN
Dr. Jeffrey Allen is a neuromuscular specialist and clinical investigator at the University of Minnesota in Minneapolis.
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
Richard A. Lewis, MD
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
  • CIDP
  • GBS
  • MMN
Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program.
Claudia Sommer, MD
University of Würzburg, Würzburg, Germany
Claudia Sommer, MD
Claudia Sommer, MD
University of Würzburg, Würzburg, Germany
  • MMN
Claudia Sommer is a Professor of Neurology at the University of W├╝rzburg, Germany.
What is Multifocal Motor Neuropathy (MMN)?
READ MORE
What are the symptoms of MMN?
READ MORE
How is MMN treated?
READ MORE

Slides & Posters about MMN

Electrophysiologic Findings In Multifocal Motor Neuropathy
PDF | 1.03 MB
Clinical Studies for the Treatment of CIDP with Immunoglobulin
PDF | 396 KB
Global Multifocal Motor Neuropathy Quality of Life Patient Survey
PDF | 1.89 MB
Pathogenesis and Mechanism of Action of Inflammatory Neuropathies
PDF | 680 KB
Back to Top